Primary nephrotic syndrome
Conditions
Interventions
Evolocumab
Sponsors
Department of Nephrology, Nippon Medical School
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Diagnosed as primary nephrotic syndrome 2) High LDL cholesterol 3) Men and women aged 16 or older when obtaining consent 4) Written consent has been obtained from the patient or family member to participate in the study. 5) Dyslipidemia patient resistant to HMG-CoA reductase inhibitors or patient who cannot use HMG-CoA reductase inhibitors because of allergies, vomiting, dyspnea, etc.
Exclusion criteria
Exclusion criteria: 1) Pregnant women 2) Secondary nephrotic syndrome 3) Clearly nephrotoxic treatment is undergoing 4) Patient judged inappropriate by the examining physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Remission rate | — |
Secondary
| Measure | Time frame |
|---|---|
| Remission introduction period, cumulative dose of prednisolone and immunosuppressant agents, reduction of the degree of proteinuria, change of serum albumin, adverse complication derived from prednisolone and immunosuppressant agents use, changes in the renal function | — |
Countries
Japan
Contacts
Public ContactRisa Asai
Department of Nephrology, Nippon Medical School Department of Nephrology
Outcome results
None listed